Bayesian Capital Management, LP Macrogenics Inc Transaction History

Bayesian Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $20,790 - $33,930	-4,500 Reduced 20.8%	17,132 $91,000
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $104,266 - $156,615	21,632 New	21,632 $155,000
Q2 2019 Aug 13, 2019	SELL	$14.51 - $19.71 $150,671 - $204,668	-10,384 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$11.11 - $25.6 $115,366 - $265,830	10,384 New	10,384 $187,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.